Praxis für Neurologie und Psychiatrie Dr. Christian Oehlwein
- Address
- Lasurstr. 27, 07551 Gera, Germany
Cardiovascular and Neurological Disorders
At Praxis für Neurologie und Psychiatrie Dr. Christian Oehlwein in Gera, clinical research spans cardiovascular diseases and nervous system diseases, with a strong focus on conditions that affect movement, blood pressure control, and day-to-day functioning.
- Studies in multiple system atrophy and neurogenic orthostatic hypotension to evaluate symptom relief and treatment benefit
- Research in Parkinson’s disease and early Parkinson’s disease aimed at improving long-term disease management
- Trials measuring whether new therapies can better support mobility, comfort, and quality of life
These trials are designed to test new treatment options and assess how well they work for neurological and autonomic symptoms in real-world patient care.
Parkinson’s Disease and Movement Disorders
The site conducts focused research in Parkinson’s disease, including early-stage disease, with studies centered on treatment effectiveness, safety, and tolerability.
- Evaluation of therapies for early Parkinson’s disease to help slow worsening of symptoms
- Assessment of long-term treatment options for improving motor and non-motor symptom control
- Clinical testing of new approaches intended to support everyday functioning in people living with Parkinsonian disorders
This work reflects a practical effort to improve care for patients with movement disorders through better symptom management and more durable treatment options.
Migraine and Headache Disorders
Clinical trials at this research site also address episodic migraine and chronic migraine, focusing on prevention and symptom reduction for adults affected by recurring headache disorders.
- Studies testing whether new therapies can help prevent migraine attacks
- Research examining safety, tolerability, and patient response in migraine care
- Trials aimed at improving control of frequent headaches and reducing their impact on daily life
By exploring preventive treatment options, the site contributes to better strategies for people living with both episodic and persistent migraine.
Dementia-Related Behavioral Symptoms
Another area of research includes agitation in patients with dementia of the Alzheimer's type, where studies are evaluating whether new therapies can help manage behavioral symptoms more effectively.
- Trials focused on reducing agitation linked to Alzheimer’s disease
- Assessment of treatment safety and tolerability in older adults with cognitive impairment
- Research aimed at improving day-to-day comfort for patients and caregivers
These studies support a broader effort to find better ways to manage challenging neuropsychiatric symptoms in dementia care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Biohaven Therapeutics Ltd.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Praxis für Neurologie und Psychiatrie Dr. Christian Oehlwein
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants with Early Parkinson’s Disease | Biohaven Therapeutics Ltd. | Phase IV | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ampreloxetine | 1 | Unknown | 2023-10-25 | 2023-10-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.